Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Synosia Therapeutics

Request full access

Therapeutics developer for central nervous system disorders

Basel, SwitzerlandFounded 2006Biotechnology

About Synosia Therapeutics

Synosia Therapeutics was a Swiss-based drug development company founded in 2005, specializing in treatments for central nervous system (CNS) disorders. The company was co-founded by Dr. Ian Massey, a veteran drug development executive with extensive experience at Roche and Syntex, who also served as President and CEO. Massey's background in neuroscience drug development was central to Synosia's strategy, which focused on acquiring or in-licensing clinical-stage assets to accelerate their path to market.

The company's business model was centered on forming strategic partnerships with major pharmaceutical firms to develop compounds that had been deprioritized. In 2007, Synosia entered into a significant agreement with Roche to develop a portfolio of five drug candidates for conditions like schizophrenia, cognitive disorders, and Parkinson's disease. This was followed by agreements with Novartis and Syngenta, expanding its pipeline to six clinical-stage compounds. A key candidate was SYN-115, an adenosine A2a antagonist for Parkinson's disease, acquired from Roche.

Synosia successfully raised significant capital to fund its clinical programs, including a $32.5 million initial funding, a $29 million Series B in 2009, and a $30 million Series C round in 2010. The Series C was led by UCB Pharma, which also entered into a strategic alliance potentially worth up to $725 million for two of Synosia's Parkinson's drugs, SYN-115 and SYN-118. In February 2011, Synosia Therapeutics was acquired by the Finnish drug development company Biotie Therapies in a deal valued at approximately €93.6 million (around $122M). Following the acquisition, Dr. Massey took on the role of COO and President of US Operations at Biotie.

Source: Dealroom company data

At a glance

Status
Acquired
Open positions
None listed
Dealroom signal
15.7/100
Client focus
B2C
Links
Website

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITIONOther financing Jan 2011 $122M — Biotie Therapies —
SERIES COther financing Oct 2010 $30M $120M 5AM Ventures · UCB · Aravis Ventures · Novo Holdings —
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Synosia Therapeutics website traffic

Latest recorded traffic for Synosia Therapeutics is 0 monthly website visits.

Latest monthly visits0
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Synosia Therapeutics in the Basel ecosystem

Live from Dealroom

The Synosia Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

9 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

  • Aravis Ventures
  • Investor Growth Capital
  • Swiss Helvetia Fund
  • Novo Ventures

Series B and later4 investors entered at this stage

Other known investors1 additional known investor

  • Biotie Therapies
Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇭 Switzerland · Basel HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Synosia Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Synosia Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.